Home › Research › TREM2 and immune genetics
Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis
Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, Albert NL, Carlsen J et al.. Frontiers in aging neuroscience, 2017-01-31
Topic: Brain proteins, microglia and lab models
Plain-language summary
Heterozygous missense mutations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been reported to significantly increase the risk of developing Alzheimer's disease (AD). Since TREM2 is specifically expressed by microglia in the brain, we hypothesized that soluble TREM2 (sTREM2) levels may increase together with in vivo biomarkers of microglial activity and amyloidosis in an AD mouse model as assessed by small animal positron-emission-tomography (μPET). In this cross-sectional study, we examined a strong amyloid mouse model (PS2APP) of four age groups by μPET with [ 18 F]-GE180 (glial activation) and [ 18 F]-florbetaben (amyloidosis), followed by measurement of sTREM2 levels and amyloid levels in the brain.
What this study adds
Evidence grade: Low
This is a cross-sectional study. In a strong amyloid mouse model (PS2APP), brain levels of soluble TREM2, a protein made by the brain's immune cells (microglia), "strongly increased with age," rising 211% between 5 and 16 months. The rise was compared against PET scans of microglial activation and amyloid plaque in the same animals.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Brendel, M., Kleinberger, G., Probst, F., Jaworska, A., Overhoff, F., Blume, T., et al. (2017). Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2017.00008
Vancouver
Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, et al. Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. Frontiers in aging neuroscience. 2017. doi:10.3389/fnagi.2017.00008. PMID: 28197095.
BibTeX
@article{brendel2017-28197095,
author = {Brendel, M. and Kleinberger, G. and Probst, F. and Jaworska, A. and Overhoff, F. and Blume, T. and Albert, N. L. and Carlsen, J. and others},
title = {{Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis}},
journal = {Frontiers in aging neuroscience},
year = {2017},
doi = {10.3389/fnagi.2017.00008},
pmid = {28197095},
url = {https://doi.org/10.3389/fnagi.2017.00008}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Since TREM2 is specifically expressed by microglia in the brain, we hypothesized that soluble TREM2 (sTREM2) levels may increase together with in vivo biomarkers of microglial activity and amyloidosis in an AD mouse model as assessed by small animal positron-emission-tomography (μPET).
- In this cross-sectional study, we examined a strong amyloid mouse model (PS2APP) of four age groups by μPET with [ 18 F]-GE180 (glial activation) and [ 18 F]-florbetaben (amyloidosis), followed by measurement of sTREM2 levels and amyloid levels in the brain.
- Pathology affected brain regions were compared between tracers (dice similarity coefficients) and pseudo-longitudinally. μPET results of both tracers were correlated with terminal TREM2 levels.
- The brain sTREM2 levels strongly increased with age of PS2APP mice (5 vs. 16 months: +211%, p R = 0.89, p R = 0.92, p in vivo μPET measurements in conjunction with post mortem sTREM2 in future anti-inflammatory treatment trials.
Why it matters
In a strong amyloid mouse model (PS2APP), brain levels of soluble TREM2, a protein made by the brain's immune cells (microglia), "strongly increased with age," rising 211% between 5 and 16 months. The rise was compared against PET scans of microglial activation and amyloid plaque in the same animals. The authors suggest combining these scans with sTREM2 in future anti-inflammatory treatment trials. This is a one-time snapshot in mice that shows association only, and it reports no treatment, cure or prevention for people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 49/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | 2 / 4 | Frontiers in Aging Neuroscience: journal h-index 174 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mouse”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 66 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.0 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 3 / 6 | Cited 3.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 13 other studies in this library |
| Still being cited | 1 / 4 | Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Axel Rominger: h-index 54 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Ludwig-Maximilians-Universität München: institution h-index 1,224 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28197095) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fnagi.2017.00008
- PubMed: 28197095
- Original source →
- Free full text: Frontiers in Aging Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.